By

Predicting IBD Treatment Responders at ECCO 2018

Personalised Anti-TNF Therapy in Crohn’s Disease trial, known as PANTS, a twelve month data, searched for the pharmacogenetic predictors of response (primary nonresponse, loss of response) and the development of antidrug antibody formation with anti-TNF agents, Infliximab and Adalimumab. PANTS will be followed by VEST, the UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease, which will be completed…